Johnson & Johnson (JNJ)
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
I Have Invested in Dividends For 15 Years—These Dividend Aristocrats Built My Passive Income Stream
These dividend aristocrats haven't disappointed me in 15 years and won't disappoint you either.
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?
JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beating consensus EPS estimates by 5.5% on average. The Q2 sales growth could potentially be the weakest of the 4 quarters of the year.
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
The vast majority of investors don't have hundreds of thousands to bet on each stock.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.
Johnson & Johnson: Patience Will Be Rewarded
Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, though below JNJ's historical average. However, I believe the market has also priced in these issues already.
